Valeant: the distributor nobody disclosed

A customer that was really a channel — and a disclosure threshold that moved.

The mechanics, laid out in the SEC's 2020 cease-and-desist order, are a masterclass in how related-party problems actually happen. Toward the end of Q3 2014, Philidor placed a $75 million order that exceeded its credit limit; Valeant approved a $70 million credit increase without the justification its own procedures required, while $8.5 million of Philidor's receivables sat more than 61 days past due. In early December 2014 came a $130 million order — approved again outside policy, with one-time special pricing at 4% above wholesale cost (no other customer paid above wholesale), an out-of-stock product swapped for a different drug in whatever quantity matched the dollar amount, and delivery arranged for a Saturday instead of the customary Monday.

Why the rush? Because on December 15, 2014, Valeant closed a $100 million option to acquire Philidor outright — fully paid, never exercised. From that date Valeant consolidated Philidor as a variable interest entity, which meant sales into Philidor could no longer be booked on delivery; revenue would have to wait until product actually sold through to patients. The $130 million order was engineered to land on the sell-in side of that line. Valeant later restated it.

On December 10, 2014, with the option about to close, Valeant raised its own disclosure thresholds — to an amount just above the Philidor purchase price — so the deal would never be named in the 10-K. The audit committee was informed.

So a pharmacy Valeant built, funded, staffed, subsidized, and held the right to own — whose shelves were 95% Valeant product — appeared nowhere in the company's MD&A, risk factors, or earnings presentations. Not when three pharmacy benefit managers told Philidor in early 2015 it was violating its network agreements. Not when an August 2015 analysis told Valeant the growth through Philidor had been mostly "subsidized (free)" by Valeant itself. The option's existence was disclosed for the first time on the Q3 2015 earnings call of October 19, 2015 — and only because journalists and short sellers were closing in.

From $262 to single digits — and a name that had to die.

The stock that touched roughly $262 in August 2015 traded below $10 by April 2017 — a decline of more than 95%, with on the order of $80 billion of market value destroyed. Bill Ackman exited in March 2017 with a multi-billion-dollar loss. Pearson was gone by mid-2016; the restated 2015 Form 10-K conceded material weaknesses in internal control over financial reporting; and in July 2018 the company buried the Valeant name itself, re-listing as Bausch Health Companies.

The legal endgame split in two. Criminally, the only convictions touched the channel itself: in 2018 former Valeant executive Gary Tanner and Philidor CEO Andrew Davenport were convicted in a $9.7 million kickback scheme around the Philidor relationship and each sentenced to a year and a day in prison. Civilly, on July 31, 2020 the SEC settled with the company for a $45 million penalty; former CEO Pearson paid a $250,000 penalty and returned $450,000 of incentive compensation under SOX Section 304, former CFO Howard Schiller paid $100,000 and returned $110,000, and former controller Tanya Carro paid $75,000 and accepted a suspension from practicing before the SEC. All settled without admitting or denying the findings — and notably, the SEC's charges were negligence-based, not fraud: no criminal case was ever brought against Pearson or Schiller.